PLS-NEO-RCCNCT07922915
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: From baseline through completion of neoadjuvant treatment, approximately 18 weeks.
Secondary (5)
Major Pathological Response (MPR) Rate
Partial Nephrectomy Success Rate
R0 Resection Rate
Surgical Complications
Adverse Events
Arms and interventions
Pucotenlimab Plus Lenvatinib and SBRTExperimental
Participants will receive neoadjuvant pucotenlimab 200 mg intravenously every 3 weeks for up to six cycles and lenvatinib 12 mg orally once daily. SBRT at 40 Gy in five fractions will be delivered to the primary renal tumor after cycle 2 and before cycle 4. Surgery is planned after neoadjuvant treatment, with partial nephrectomy preferred when feasible.
Drugs: Pucotenlimab, Lenvatinib
Radiation: Stereotactic Body Radiotherapy